Algert Global LLC Has $2.16 Million Stock Holdings in Progyny, Inc. (NASDAQ:PGNY)

Algert Global LLC trimmed its position in Progyny, Inc. (NASDAQ:PGNY) by 32.4% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 124,937 shares of the company’s stock after selling 59,948 shares during the quarter. Algert Global LLC owned approximately 0.15% of Progyny worth $2,155,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Leibman Financial Services Inc. grew its position in shares of Progyny by 100.7% during the 4th quarter. Leibman Financial Services Inc. now owns 63,509 shares of the company’s stock worth $1,096,000 after buying an additional 31,872 shares during the period. Fort Washington Investment Advisors Inc. OH grew its holdings in Progyny by 90.1% during the 4th quarter. Fort Washington Investment Advisors Inc. OH now owns 1,467,780 shares of the company’s stock worth $25,319,000 after acquiring an additional 695,740 shares during the period. Clear Harbor Asset Management LLC bought a new stake in shares of Progyny during the 4th quarter valued at $989,000. Barclays PLC lifted its stake in shares of Progyny by 530.4% in the 3rd quarter. Barclays PLC now owns 706,157 shares of the company’s stock valued at $11,835,000 after purchasing an additional 594,140 shares during the period. Finally, Baillie Gifford & Co. lifted its stake in shares of Progyny by 52.2% in the 4th quarter. Baillie Gifford & Co. now owns 1,332,690 shares of the company’s stock valued at $22,989,000 after purchasing an additional 456,853 shares during the period. 94.93% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of equities research analysts recently commented on the company. BTIG Research upgraded Progyny from a “neutral” rating to a “buy” rating and set a $28.00 price objective for the company in a report on Monday, March 31st. Canaccord Genuity Group increased their price target on shares of Progyny from $17.00 to $23.00 and gave the company a “hold” rating in a research report on Friday, February 28th. JPMorgan Chase & Co. boosted their price objective on shares of Progyny from $17.00 to $23.00 and gave the company a “neutral” rating in a report on Tuesday, January 28th. Finally, Bank of America increased their target price on shares of Progyny from $21.00 to $25.00 and gave the stock a “buy” rating in a report on Tuesday, February 11th. Eight equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat, Progyny currently has an average rating of “Hold” and an average price target of $23.64.

Progyny Trading Down 0.1 %

Shares of NASDAQ PGNY opened at $23.40 on Friday. The company has a fifty day moving average price of $21.96 and a 200 day moving average price of $19.47. The firm has a market cap of $2.00 billion, a PE ratio of 40.34, a PEG ratio of 2.39 and a beta of 1.37. Progyny, Inc. has a 1-year low of $13.39 and a 1-year high of $32.57.

Progyny (NASDAQ:PGNY) last posted its quarterly earnings data on Thursday, May 8th. The company reported $0.17 earnings per share for the quarter, missing the consensus estimate of $0.45 by ($0.28). Progyny had a return on equity of 11.36% and a net margin of 5.03%. During the same period last year, the firm earned $0.17 EPS. Progyny’s quarterly revenue was up 16.5% compared to the same quarter last year. Equities research analysts forecast that Progyny, Inc. will post 0.6 EPS for the current year.

Progyny Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.